Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study
The LancetPublished 1 May 1997Open access
CAPTURE, STGRP, non vooting member Tijssen, J.
Citations1,338
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
In patients with refractory unstable angina, treatment with abciximab substantially reduces the rate of thrombotic complications, in particular myocardial infarction, before, during, and after PTCA.
Abstract
In patients with refractory unstable angina, treatment with abciximab substantially reduces the rate of thrombotic complications, in particular myocardial infarction, before, during, and after PTCA. There was no evidence that this regimen influenced the rate of myocardial infarction after the first few days, or the need for subsequent reintervention.
Keywords
Medicine
New England Journal of MedicineA Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease
4,540 Citations1994Patrick W. Serruys, Peter de Jaegere +15 more
The clinical and angiographic outcomes were better in patients who received a stent than in those who received standard coronary angioplasty, however, this benefit was achieved at the cost of a significantly higher risk of vascular complications at the access site and a longer hospital stay.
New England Journal of MedicineA Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease
4,243 Citations1994David L. Fischman, Martin B. Leon +22 more
In selected patients, placement of an intracoronary stent, as compared with balloon angioplasty, results in an improved rate of procedural success, a lower rate of angiographically detected restenosis, a similar rate of clinical events after six months, and a less frequent need for revascularization of the original coronary lesion.
New England Journal of MedicineUse of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
2,602 Citations1994The EPIC Investigators
Ischemic complications of coronary angioplasty and atherectomy were reduced with a monoclonal antibody directed against the platelet IIb/IIIa glycoprotein receptor, although the risk of bleeding was increased.
New England Journal of MedicineA Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery Stents
2,024 Citations1996Albert Schömig, Franz–Josef Neumann +10 more
Combined antiplatelet therapy after the placement of coronary-artery stents reduces the incidence of both cardiac events and hemorrhagic and vascular complications as compared with conventional anticoagulant therapy.
HeartPlaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina.
1,990 Citations1985Michael J. Davies, Anthony Thomas
This controversy was concerned with whether coronary artery thrombi were or were not directly responsible for all three clinical pictures of acute ischaemia.
BiometrikaDiscrete sequential boundaries for clinical trials
1,740 Citations1983K. K. Gordon Lan, David L. DeMets
A more flexible way to construct discrete sequential boundaries is proposed, based on the choice of a function, a*(t), which characterizes the rate at which the error level ac is spent.
New England Journal of MedicineAspirin, Heparin, or Both to Treat Acute Unstable Angina
1,278 Citations1988Pierre Théroux, Hélène Ouimet +11 more
It is concluded that in the acute phase of unstable angina, either aspirin or heparin treatment is associated with a reduced incidence of myocardial infarction, and there is a trend favoringHeparin over aspirin.
CirculationUnstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion.
1,051 Citations1985Erling Falk
The period of unstable angina before the final heart attack was, in all but one of 15 patients, characterized by such an ongoing thrombotic process in a major coronary artery where recurrent mural thrombus formation seemed to have alternated with intermittentThrombus fragmentation.
Journal of the American College of CardiologyThrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
988 Citations1988Anupama Rao, Craig M. Pratt +8 more
In the doses administered, rt-PA induces systemic fibrinogenolysis that is substantially less intense than that induced by streptokinase, and emphasize the need for avoidance of invasive procedures and for meticulous care in the selection and management of patients subjected to thrombolytic therapy.
The LancetRandomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months
841 Citations1994Eric J. Topol, R.M. Califf +12 more
A monoclonal antibody Fab fragment directed against the platelet glycoprotein IIb/IIIa integrin, the receptor mediating the final common pathway of platelet aggregation, reduced the frequency of clinical restenosis in patients with unstable angina and carried a risk of bleeding complications.
Journal of Clinical InvestigationA murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.
760 Citations1983Barry S. Coller, Ellinor I.B. Peerschke +2 more
There is probably a single anatomic site that is crucial to the binding of all fibrinogen molecules and that this site is most likely on the glycoprotein IIb/IIIa complex, according to studies of a murine monoclonal antibody produced by the hybridoma technique.
CirculationHeparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries
404 Citations1996Patrick W. Serruys, Håkan Emanuelsson +19 more
The implantation of stents coated with polyamine and end-point-attached heparin in stable patients with one significant de novo coronary lesion is well tolerated, is associated with no (sub)acute stent thrombosis, and results in a favorable event-free survival after 6 months.
Annals of Internal MedicinePractice Strategies for Elective Red Blood Cell Transfusion
347 Citations1992
The following clinical guideline is based on the background paper "Prudent Strategies for Elective Red Blood Cell Transfusion, "published in this issue of Annals.
CirculationAcute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Frequency, prediction, clinical course, management, and follow-up.
291 Citations1991Pim J. de Feyter, Marcel van den Brand +5 more
Acute coronary artery occlusion during PTCA is often unpredictable, but its frequency is higher in patients with unstable angina, multivessel disease, and complex lesions, which is associated with a high mortality and morbidity.
The American Journal of MedicineIdentification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy
266 Citations1987C. Seth Landefeld, E. Francis Cook +3 more
Among 617 hospitalized patients who started long-term anticoagulant therapy, major bleeding developed before discharge in 28 patients and minor bleeding in another 38, with daily incidence rates of 0.4 and 0.5 percent, respectively.
CirculationRandomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.
245 Citations1994M. L. Simoons, M. J. de Boer +8 more
Combined therapy with c7E3 Fab, heparin, and aspirin appears safe and supports the concept that effective blockade of the platelet GPIIb/IIIa receptors can reduce myocardial infarction and facilitate PTCA in patients with refractory unstable angina.
CirculationBleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Integrin in Patients Undergoing Percutaneous Coronary Intervention
242 Citations1995Frank V. Aguirre, Eric J. Topol +12 more
Bleeding complications unrelated to bypass surgery were two to three times more frequent in patients receiving c7E3 Fab than in those receiving placebo, but most were transient and well tolerated, and risk-factor analysis and modification of concomitant antithrombotic and antiplatelet treatment strategies may aid in reducing bleeding complications and enhancing clinical benefit.
Journal of Vascular SurgeryInhibition of neointimal hyperplasia by blocking αvβ3 integrin with a small peptide antagonist GpenGRGDSPCA*
194 Citations1994Eric T. Choi, Leslie Engel +5 more
The important role of the alpha V beta 3 integrin in SMC migration in vitro and in neointimal hyperplasia in vivo is demonstrated.
Journal of the American College of CardiologyIncidence and follow-up of Braunwald subgroups in unstable angina pectoris
161 Citations1995Addy J.M. van Miltenburg-van Zijl, Maarten L. Simoons +2 more
Elderly age, male gender, hypertension, class C and maximal (intravenous) therapy were independent predictors for death; elderly age and class C for infarct-free survival; andmale gender, class III,class C, electrocardiographic changes and maximal therapy were associated with infar CT survival without intervention.
CirculationEconomic Assessment of Platelet Glycoprotein IIb/IIIa Inhibition for Prevention of Ischemic Complications of High-Risk Coronary Angioplasty
137 Citations1996Daniel B. Mark, J. David Talley +11 more
In high-risk coronary angioplasty, aggressive platelet inhibition with c7E3 Fab, by significantly reducing ischemic events and repeat revascularization, recoups most of the cost of therapy and has the potential to pay for itself.
European Heart Journallschaemic heart disease: Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial
98 Citations1996Peter Klootwijk, Anatoly Langer +7 more
It is concluded that continuous ECG monitoring may help select high risk patients without apparent reperfusion who may benefit from additional reperfusions therapy, as ST recovery may occur early after the start of thrombolytics and accuracy of the test is related to peak ST levels.
European Heart JournalComparison of usefulness of computer assisted continuous 48-h 3-lead with 12-lead ECG ischaemia monitoring for detection and quantitation of ischaemia in patients with unstable angina
63 Citations1997Peter Klootwijk, S. Meij +5 more
Continuous 12- lead ST monitoring increases detection rate and duration of ST episodes compared to 3-lead ST monitoring and the use of continuous 12-lead ECG monitoring devices on emergency wards and coronary care units is recommended.
European Heart JournalCoronary intervention: Risk stratification and management of abrupt coronary occlusion
18 Citations1995Pim J. de Feyter, Peter Ruygrok
Clinical, angiographic and lesion variables predictive of risk of abrupt occlusion are reviewed and a low, medium and high risk profile stratification is developed.